Publication details

DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023

Authors

DEMLOVÁ Regina KUBELOVÁ Michaela

Year of publication 2023
MU Faculty or unit

Faculty of Medicine

Web RASMIR
Description Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study.

You are running an old browser version. We recommend updating your browser to its latest version.

More info